Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison.

BMJ Oncol · 2025 · PMC13064201 · PMID 41971757

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

35 They found that, compared with NIVO+RELA, NIVO+IPI had similar PFS and ORR, while BRAF/MEK inhibitors had similar PFS and significantly higher ORR; NIVO+RELA also showed a trend of fewer grade ≥3 AEs than NIVO+IPI.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.